Mira Pharmaceuticals advances new preclinical studies using Ketamir-2

Mira Pharmaceuticals announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder and other leading mental health disorders and neuropathic pain indications. Mira continues to advance studies of Ketamir-2 in animal studies while improving manufacturing optimization as the company prepares for human testing in 2025. Mira anticipates that positive results from these preclinical studies will enable the submission of an Investigational New Drug Application to the U.S. FDA by the end of this year, which if cleared by FDA would allow for human clinical testing of Ketamir-2.